Has Edward Gelmann received payments from drug or device companies?

Yes. Drug and device makers reported $944,167 in general payments to Edward Gelmann across 21 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edward Gelmann did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edward Gelmann come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edward Gelmann

Medical Oncology · New York, NYNPI 1285632067

Payments from drug & device makers

What this record shows

This record is dominated by other: $943,437 of the $944,167 with a category attached, or 99.9%. Zimmer Biomet accounts for 99.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $943,509 and has fallen 100.0% since, to $79 in 2025. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$944,167in general payments, 2019–2025

Across 21 payments — averaging $44,960 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Zimmer Biomet$943K
Sanofi$379
Boehringer Ingelheim$82
Pfizer$77
Genentech, Inc.$57
AstraZeneca$48
plus $85 from 4 others

$1,987,352in research payments, 2019–2025

Across 429 payments — averaging $4632.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$1.3M
Biontech SE$415K
Genentech, Inc.$97K
Bayer$80K
Pharmacyclics LLC, An Abbvie Company$62K
Merck$30K
plus $49K from 2 others

$1,012,679in ownership & investment interests, 2019–2025

Across 3 payments — averaging $337,560 each. An ownership or investment interest held by the physician or an immediate family member.

Zimmer Biomet$1M

What the payments were for

Travel & lodging$2520%
Food & beverage$4600%
Education$180%
Other$943,437100%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Zimmer Biomet	3	$943,437
Sanofi	6	$379
Boehringer Ingelheim	1	$82
Pfizer	4	$77
Genentech, Inc.	1	$57
AstraZeneca	2	$48
Beigene USA, Inc.	1	$29
Lilly USA, LLC	1	$26
E.r. Squibb & Sons, L.L.C.	1	$18
Amgen	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TAPESTRY$943,316
NO PRODUCT DISCUSSED$287

How this compares

$944,167 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$89,458

Medicare patients

254

Services billed

747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	112	$1,552,452
ErleadaApalutamide	49	$711,242
Abiraterone Acetate	252	$313,317
OrgovyxRelugolix	14	$40,811
Prednisone	218	$843
Tamsulosin Hcl	14	$597
Ondansetron Hcl	26	$384
Morphine Sulfate ErMorphine Sulfate	34	$300
Potassium Chloride	14	$180
Levothyroxine Sodium	21	$136
Lorazepam	26	$116
Oxycodone Hcl	13	$106

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K
David SolitNew York$352K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →